Targeted Medical Pharma Reports New Data on Red Blood Cell Stimulating Formulation

Before you go, we thought you'd like these...
Before you go close icon

Targeted Medical Pharma Reports New Data on Red Blood Cell Stimulating Formulation

LOS ANGELES--(BUSINESS WIRE)-- Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biopharmaceutical company that develops and distributes prescription medical foods to physicians and pharmacies, today unveiled new results from an open label study of its oral amino acid-based erythrocyte stimulating system (ESS) for the treatment of chronic anemia. The company's ESS system is designed to stimulate progenitor stem cells in the bone marrow.


Subjects in the study diagnosed with mild to moderate anemia were administered 1800mg of the company's oral formulation daily for seven days. Each subject underwent weekly blood sampling, including hemoglobin, hematocrit and reticulocyte count for four weeks from the initial dosing, and once more 45 days following the initial dose. Hemoglobin increased an average of 11.39 percent from baseline measurement to 45 days. The average baseline hemoglobin measurement was 10.08 and 11.21 after 45 days with a similar increase in reticulocyte count (p<0.01).

"This is the first demonstration that an oral stimulation of progenitor red blood cells with a targeted amino acid therapy can initiate progenitor stem cell conversion of undifferentiated red blood cells to mature red blood cells with an increase in hemoglobin content in patients with chronic anemia," said William Shell, M.D., CEO of Targeted Medical Pharma, Inc. "Developing an oral system for stimulating mature blood cells from progenitor cells is a milestone for our company and may represent a method to modulate red blood cell function in patients with anemia."

Preliminary results of the study released last year also found a 16 percent increase in hemoglobin and a 450 percent increase in peripheral reticulocytes over a seven day period (p<0.01) among normal volunteers taking ESS. The company plans to perform further testing of its red blood cell stimulating system and to explore treatment applications in other forms of anemia.

Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that developsprescription medical foods for the treatment of chronic disease including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures ten proprietary prescription only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company's subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release regarding data results of an investigational study of a new formulation affecting the hemopoetic systemmay contain forward-looking statements related to the company's business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.



Media Contacts:
PondelWilkinson
George Medici, gmedici@pondel.com
Ron Neal, rneal@pondel.com
310-279-5980
or
Investor Contacts:
PondelWilkinson
Roger Pondel / Matt Sheldon
investors@tmedpharma.com
310-279-5975

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Targeted Medical Pharma Reports New Data on Red Blood Cell Stimulating Formulation originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners